GRACELL BIOTECHNOLOGIES INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Indemnification Agreement (this “Agreement”) is made as of , by and between Gracell Biotechnologies Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and [Name of Director] ([US passport/ID]:[*])
Working Capital (in RMB) Loan ContractGracell Biotechnologies Inc. • December 18th, 2020 • Pharmaceutical preparations
In view of the need of paying for goods, Party A applies for a loan to Party B, and Party B agrees to issue a loan to Party A. This Contract has been entered into by and between both parties through negotiation and in accordance with relevant laws, regulations and rules for mutual compliance.
Voting Rights Proxy AgreementVoting Rights Proxy Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
(In this Agreement, each of Party A, Party B and Party C shall be referred to as a “Party” respectively, and they shall be collectively referred to as the “Parties”.)
GRACELL BIOTECHNOLOGIES INC. DIRECTOR AGREEMENTDirector Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Director Agreement (the “Agreement”) is made and entered into as of , by and between Gracell Biotechnologies Inc., a Cayman Islands company (the “Company”), and (ID Card No.: ) (the “Director”).
Amendment to Call Option AgreementCall Option Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Amendment to Call Option Agreement (this “Agreement”) is executed by and among the following Parties as of November 10, 2020 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
Call Option AgreementCall Option Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Call Option Agreement (this “Agreement”) is executed by and among the following Parties as of November 10, 2020 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
EXCLUSIVE LICENSE AGREEMENT [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because Gracell Biotechnologies Inc. has determined it is not material and would be competitively harmful if publicly...Exclusive License Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations • California
THIS AGREEMENT is made and entered into on April 19th , 2017 (hereinafter “EFFECTIVE DATE”) by and between ProMab Biotechnologies, Inc. a corporation, whose address is 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA 94806 USA (hereinafter “PROMAB”) and Unitex Capital Ltd., a BVI limited liability company, whose address is 1208 E. Arques Ave., Sunnyvale, CA 94085 (hereinafter “LICENSEE”). PROMAB and LICENSEE are sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties”.
Technical Consultation and Service AgreementConsultation and Service Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Technical Consulting and Services Agreement (the “Agreement”) is entered into as of January 3, 2019 in Shanghai, People’s Republic of China (“PRC” or “China”) between the following two parties:
Equity Pledge Supplementary AgreementEquity Pledge Supplementary Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Equity Pledge Supplementary Agreement (this “Agreement”) has been executed by and among the following parties on November 10, 2020 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
Equity Pledge AgreementEquity Pledge Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Equity Pledge Agreement (this “Agreement”) has been executed by and among the following parties on November 10, 2020 in Shanghai, the People’s Republic of China (“China” or the “PRC”):
Business Cooperation AgreementBusiness Cooperation Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Business Cooperation Agreement (this “Agreement”) is made and entered into by and between the following parties on January 3, 2019 in Shanghai, the People’s Republic of China (“China” or the “PRC”).
GRACELL BIOTECHNOLOGIES INC. SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENTShareholders Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations • Hong Kong
THIS SECOND AMENDED AND RESTATED SHAREHOLDERS AGREEMENT (this “Agreement”) is made and entered into on October 20, 2020 by and among:
GRACELL BIOTECHNOLOGIES INC. EMPLOYMENT AGREEMENTEmployment Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations • Hong Kong
This Employment Agreement (the “Agreement”) is made and entered into as of , by and between Gracell Biotechnologies Inc., a Cayman Islands company (the “Company”), and (ID Card No.: ) (the “Employee”).
AMENDED AND RESTATED No.1 TO EXCLUSIVE LICENSE AGREEMENT WITH SUBLICENSING TERMS [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because Gracell Biotechnologies Inc. has determined it is not...Exclusive License Agreement • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
This Amended and Restated Agreement (“Agreement”) is made effective November 29th , 2017 (the “Effective Date”) by and between ProMab Biotechnologies, Inc (hereinafter called “PROMAB”), a company having its principle office at 2600 Hilltop Drive, Building B, Suite C320, Richmond, CA94806, and Unitex Capital Ltd (hereinafter called “LICENSEE”), a company having its principle office at 1208 E. Arques Ave., Sunnyvale, CA 94085 and Gracell Biotechnologies Co. Ltd. 亘喜生物科技（上海）有限公司 (hereinafter called “亘喜”), a company having its principle office at Level 12, No.926 Yishan Road, Shanghai China. PROMAN, LICENSEE and 亘喜 are at times referred to in this Agreement as “the parties”.
Fixed Assets Loan Contract No.: 512HT2020104831Fixed Assets • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations • Hong Kong
☐ This Contract is a specific Contract under the Credit Extension Agreement numbered / (If this article is applicable, check the box).
Working Capital (in RMB) Loan ContractWorking Capital • December 18th, 2020 • Gracell Biotechnologies Inc. • Pharmaceutical preparations
In view of the need of paying for goods, Party A applies for a loan to Party B, and Party B agrees to issue a loan to Party A. This Contract has been entered into by and between both parties through negotiation and in accordance with relevant laws, regulations and rules for mutual compliance.
